JPMorgan Equity Premium Income ETF vs Twist Bioscience Corp — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.84, while Twist Bioscience Corp trades at $123.93 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPI | TWST | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $124.88 |
52-Week Low | $55.29 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $57.86, up 0.37% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on generating income through covered calls, offering monthly dividends, though recent news highlights underperformance versus peers and tax inefficiencies. Key support and resistance cluster around $58.
Outlook is mixed: JEPI provides steady income attractive to retirees, but faces competition from higher-yielding alternatives and potential opportunity cost from capped upside. Risks include yield compression, tax treatment of distributions, and active management underperformance. Investors should weigh income needs against total return potential.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Trailing returns across standard periods
Latest headlines on both assets
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →